Context: Glycemic control is limited by the barrier of hypoglycemia. Recurrent hypoglycemia impairs counterregulatory (CR) hormone responses to subsequent hypoglycemia.

Objective: To determine the glucagon and epinephrine responses to insulin-induced hypoglycemia in adolescents with recent-onset type 1 diabetes mellitus (T1DM).

Methods: We assessed the CR responses to hypoglycemia by performing a hyperinsulinemic (2.0 mU/kg/min), euglycemic (BG 90 mg/dL; 5.0 mmol/L)-hypoglycemic (BG 55 mg/dL; 3.0 mmol/L) clamp in 25 recent-onset (<1 yr duration) patients 9-18 yr old (mean ± SD: 13.4 ± 2.7) with T1DM and 16 non-diabetic controls 19-25 yr old (mean ± SD 23.3 ± 1.8). Twenty of the T1DM subjects were retested 1-yr (53 ± 3 wk) later.

Results: At the initial and 1-yr studies, peak glucagon (pGON) and incremental glucagon (ΔGON) during hypoglycemia were lower in the T1DM subjects [median pGON = 47 pg/mL (quartiles: 34, 72), ΔGON = 16 (4, 27) initially and pGON = 50 pg/mL (42, 70), ΔGON = 12 (9, 19) at 1-yr] than in controls [pGON = 93 pg/mL (60, 111); ΔGON = 38 pg/mL (19, 66), p = 0.01 and p = 0.004 for ΔGON at initial and 1-yr study, respectively]. In contrast, peak epinephrine (pEPI) and incremental epinephrine (ΔEPI) levels were similar in the T1DM (pEPI = 356 pg/mL (174, 797) and ΔEPI = 322 pg/mL (143, 781) initially and pEPI = 469 pg/mL (305, 595) and ΔEPI = 440 pg/mL (285, 574) at 1 yr) and in controls (pEPI = 383 pg/mL (329, 493) and ΔEPI = 336 pg/mL (298, 471) p = 0.97 and 0.21 for ΔEPI at initial and 1-yr study, respectively).

Conclusions: Even within the first year of T1DM, glucagon responses to hypoglycemia are blunted but epinephrine responses are not, suggesting that the mechanisms involved in the loss of these hormonal responses, which are key components in pathophysiology of hypoglycemia-associated autonomic failure, are different.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858506PMC
http://dx.doi.org/10.1111/pedi.12070DOI Listing

Publication Analysis

Top Keywords

glucagon epinephrine
8
epinephrine responses
8
responses hypoglycemia
8
type diabetes
8
diabetes mellitus
8
hypoglycemia
5
blunted glucagon
4
responses
4
hypoglycemia occurs
4
occurs youth
4

Similar Publications

Type 1 diabetes (T1D) is characterized by the autoimmune destruction of pancreatic beta cells, leading to absolute insulin deficiency and the need for exogenous insulin. A significant concern in T1D management is hypoglycemia, which is worsened by impaired counterregulatory mechanisms. Effective counterregulation involves hormones such as glucagon and adrenaline, which work to restore normal blood glucose levels.

View Article and Find Full Text PDF
Article Synopsis
  • Postprandial hypoglycaemia (PPHG) is a common complication after Roux-en-Y gastric bypass (RYGB) in individuals with a history of type 2 diabetes, often occurring without symptoms.
  • A study of 24 patients showed that PPHG results from an excessive clearance of glucose and hyperinsulinaemia, linked to higher insulin sensitivity and enhanced beta cell function.
  • Those experiencing PPHG had poor hormonal responses to low blood sugar, leading to more frequent and prolonged hypoglycaemia, which affected their eating habits over time.
View Article and Find Full Text PDF

Hypoglycemia in Pregnant Women with Type 1 Diabetes: Is It Inevitable?

Am J Perinatol

November 2024

Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Inova Health System, Fairfax, Virginia.

The human body has abundant mechanisms to counteract hypoglycemia and prevent neuroglycopenia primarily involving the secretion of glucagon and adrenalin. Within several years from the onset of diabetes, people with type 1 diabetes lose their ability to mount a counterregulatory response to hypoglycemia and develop hypoglycemia unawareness, thus being at risk for deteriorating to a state of severe hypoglycemia and neuroglycopenia. Pregnant individuals with type 1 diabetes are particularly prone to experience severe hypoglycemia during the first half of pregnancy.

View Article and Find Full Text PDF

Fasting as an Adjuvant Therapy for Cancer: Mechanism of Action and Clinical Practice.

Biomolecules

November 2024

Guangdong Provincial Key Laboratory for Research and Evaluation of Pharmaceutical Preparations, Department of Biotechnology, School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou 510006, China.

The fundamental biological characteristics of tumor cells are characterized by irregularities in signaling and metabolic pathways, which are evident through increased glucose uptake, altered mitochondrial function, and the ability to evade growth signals. Interventions such as fasting or fasting-mimicking diets represent a promising strategy that can elicit distinct responses in normal cells compared to tumor cells. These dietary strategies can alter the circulating levels of various hormones and metabolites, including blood glucose, insulin, glucagon, growth hormone, insulin-like growth factor, glucocorticoids, and epinephrine, thereby potentially exerting an anticancer effect.

View Article and Find Full Text PDF
Article Synopsis
  • - Growth differentiation factor 15 (GDF15) increases during exercise and is linked to higher levels of corticosterone and fat utilization, but its exact role during recovery from exercise remains unclear.
  • - This study investigated how postexercise nutrient availability affects GDF15 levels and examined its relationship with corticosterone and various metabolic indicators in mice.
  • - Findings showed that while GDF15, corticosterone, and certain fatty acids increased immediately after exercise, the relationships observed were not causal, as similar responses were seen in both normal and GDF15-deficient mice.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!